Medtronic Pioneers National Coverage Analysis for Symplicity Spyral

Deal News | Jan 13, 2025 | Sanderling Ventures

Medtronic Pioneers National Coverage Analysis for Symplicity Spyral

Medtronic plc, a leader in healthcare technology, has announced that the Centers for Medicare & Medicaid Services (CMS) is initiating a national coverage analysis for the company's Symplicity Spyral renal denervation system. This system provides a minimally invasive treatment for hypertension. This analysis aims to establish a national Medicare coverage policy, enhancing patient access to this innovative device. The Symplicity Spyral is noted for long-term efficacy, as demonstrated in global clinical trials with over 4,000 participants. This process marks the first national coverage analysis for such a treatment, highlighting a significant milestone in addressing global hypertension challenges.

Sectors

  • Healthcare Technology
  • Medical Devices

Geography

  • Ireland – Medtronic plc, the company at the focus of the article, is headquartered in Galway, Ireland.
  • United States – The article references the Centers for Medicare & Medicaid Services (CMS) in the U.S., which is conducting the national coverage analysis.

Industry

  • Healthcare Technology – The article discusses Medtronic's technology-driven approach in healthcare, particularly the innovative Symplicity Spyral renal denervation system.
  • Medical Devices – Symplicity Spyral is a medical device aimed at treating hypertension through renal denervation.

Financials

  • Over 4,000 patients – Size of the clinical program studying the efficacy of the Symplicity Spyral renal denervation system.

Participants

NameRoleTypeDescription
Medtronic plcTarget CompanyCompanyA global leader in healthcare technology focused on the development of the Symplicity Spyral renal denervation system.
Sanderling VenturesPE FirmCompanyA private equity firm mentioned in connection with Medtronic.
Centers for Medicare & Medicaid Services (CMS)GovernmentGovernmentA U.S. government agency conducting the national coverage analysis for the Symplicity Spyral renal denervation system.